Become A Featured Company

Tetra Bio-Pharma: Defending & Validating Smoked Cannabis

Ryan Allway

July 5th, 2017

News, Top News

Cannabis has been consumed via smoking for several hundred years, but the rise and fall of the tobacco industry has caused concern among the public. While tobacco conclusively causes cancer, cannabis smoke has a very different composition that regulators, physicians, and patients should consider. Smoking small quantities of medical marijuana may be perfectly safe for users and provide benefits that pharmacological compositions cannot.

In this article, we will look at Tetra Bio-Pharma Inc. (CSE: TBP) (OTCQB: TBPMF) and its clinical approach to defending the use of dried marijuana to treat patients in Canada.

Dispelling Myths

Smoking is widely perceived as unhealthy at best and carcinogenic at worst. And, for good reason: Smoking tobacco kills more people than alcohol, car accidents, HIV, guns, and illegal drugs combined and shortens lives by 11 to 12 years, according to the American Cancer Society. The problem is that many people group tobacco with cannabis when the two drugs are very different in the way that they impact the body.

The National Academies of Sciences, Engineering and Medicine recently conducted the most comprehensive study ever on medical marijuana. Researchers found evidence that suggests smoking cannabis does not increase the risk for cancers often associated with tobacco use – such as lung and head and neck cancers. Most medical marijuana patients only consume one cigarette per day, which limits the effects on the respiratory system.

“Society has to focus on caring for all patients living with pain, not just those that want a different dosage form,” said Tetra Bio-Pharma CEO Dr. Guy Chamberland. “In fact, our challenge is to characterize the safety and efficacy of this therapy, ensure lot-to-lot quality, provide adequate risk information to health professionals, demonstrate the safety and efficacy so that physicians can adequately assess the potential efficacy and safety for their patients, and actively pursue more tolerable dosage forms to offer these innovative cannabis therapies to patients.”

Unique Approach

Tetra Bio-Pharma’s PPP-001 aims to become the first smokable marijuana prescription product for advanced cancer pain. After successfully completing a Phase I clinical trial, the company is preparing to launch a Phase III clinical trial during the fourth quarter of this year. Management will also seek out a commercialization partner at the same time before seeking final marketing approval for the drug, planned during the fourth quarter of 2019.

The company’s approach to the market is unique for several reasons. By using a smokable form of the drug, the company doesn’t have the same investment risk as a “new chemical entity” that requires much more extensive clinical approvals. The delivery mechanism is also well-understood by patients that have experience smoking cannabis, which means that there are no new significant habits to form or changes for them to make.

Finally, raw cannabis has a so-called “entourage effect” that many synthetic cannabinoids may fail to effectively capture. The interaction between THC, CBD, and hundreds of other cannabinoids present in the marijuana plant may work together to enhance the drug’s effectiveness. This is clearly demonstrated in experiments where patients were given just THC versus a combination of THC-CBD with the latter producing far superior results.

Looking Ahead

Tetra Bio-Pharma Inc. (CSE: TBP) (OTCQB: TBPMF) has taken a unique approach to the cannabis industry by advancing smoked cannabis products through clinical trials. Investors may want to take a closer look at the stock with its modest market capitalization and significant potential with its PPP-001 program and other ventures across human and veterinary markets.

For more information, visit the company’s website, their investor presentation, or CannabisFN’s company profile.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading